Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00545519 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT00545519 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that has completed, run by Washington University School of Medicine. The registered enrollment target is 6 participants, below the 342-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00545519, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients. To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with Thymoglobulin. To determine the time to response, duration of response, and time to progression and overall survival of patients treated with Thymoglobulin. To determine the safety and tolerability of Thymoglobulin in these patients. To assess the changes in lymphocyte apoptosis and apoptotic signaling in treated patients.
Conditions Studied
Interventions
- DRUG thymoglobulin
Study Locations (1)
Missouri
- Washington Unvierstiy in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00545519
The ClinicalTrials.gov registry entry for NCT00545519 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 342-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (98% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which thymoglobulin is the first listed.
NCT00545519 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00545519 about?
NCT00545519 is a clinical study titled "A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma". To determine the maximum tolerated dose and dose limiting toxicity of thymoglobulin in multiple myeloma patients. To determine the overall response rate (CR+PR) of patients with relapsed or refractory multiple myeloma treated with Thymoglobulin. To determine the time to response, duration of respo...
What is the current status of trial NCT00545519?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2006-10. Estimated completion is 2008-03.
What conditions does trial NCT00545519 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT00545519?
The interventions under investigation include: thymoglobulin (DRUG).
Who is sponsoring clinical trial NCT00545519?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00545519 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
-
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
COMPLETED · Phase 1
-
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.